Quadrant Capital Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Quadrant Capital Group’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-949	Closed	-$20.5K	–	2715
2025 Q4	$20.5K	Hold	949	–	–	﹤0.01%	1985
2025 Q3	$14.5K	Buy	+949	New	+$12.3K	﹤0.01%	2052
2025 Q2	–	Sell	-617	Closed	-$4.83K	–	1447
2025 Q1	$4.83K	Buy	+617	New	+$5.17K	﹤0.01%	2357

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Quadrant Capital Group's AVDL Position: Q1 2026 in Review

Quadrant Capital Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 949 shares — an estimated $20.5K sold.

Quadrant Capital Group first reported a position in AVDL in Q1 2025 and held it in 3 quarters. The position peaked at $20.5K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Quadrant Capital Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Quadrant Capital Group sold 949 Avadel Pharmaceuticals shares in Q1 2026, an estimated $20.5K.
Quadrant Capital Group first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 3 quarters.
Quadrant Capital Group's Avadel Pharmaceuticals position peaked at $20.5K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.